key: cord-1013425-gxi0vmg3
authors: Ray, Joel G.; Colacci, Michael; Schull, Michael J; Vermeulen, Marian J; L Park, Alison
title: Non-ABO red cell antibodies and risk of COVID-19
date: 2021-05-19
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.05.038
sha: fb1fb1a8e869460a0594c06a3533bc877b9c5662
doc_id: 1013425
cord_uid: gxi0vmg3

It is not known whether non-ABO antibodies confers any protective effect against SARS-CoV-2 infection or COVID-19 severe illness, alone, or in conjunction with O blood group. This cohort study included 413,576 persons in Ontario, Canada with known ABO blood group and non-ABO antibody screen status, and who subsequently underwent SARS-CoV-2 viral RNA PCR testing between January and November 2020. The risk of SARS-CoV-2 infection or COVID-19 severe illness was not associated with the presence of non-ABO antibodies, even among persons with O blood group.

Keywords: SARS-CoV-2; COVD-19; ABO blood group; non-ABO blood group antibodies

Persons with blood group O may be at lower risk of SARS-CoV-2 infection and COVID-19related severe illness (Ray et al., 2020) . The SARS-COV-2 Spike (S) glycoprotein is responsible for its attachment and entry across the host cell membrane. Since A or B epitopes may be present on the viral S glycoprotein, the anti-A and anti-B antibodies of persons with O blood group may neutralize the virus, by binding to corresponding antigens on the viral envelope (Pendu et al., 2021) . A and B antigens are synthesized by epithelial cells of the respiratory and digestive tract, where COVID-19 tissue injury can occur (Pendu et al., 2021) .

There also exist hundreds of non-ABO blood group antibodies, typically arising following sensitization with red cell transfusion or pregnancy (Gehrie and Tormey, 2014) . Non-ABO antibodies are routinely tested at a patient's blood group and screen, and include Rhesus, Kell, Lewis, Lutheran, Duffy, Kidd and P antigens (Gehrie and Tormey, 2014) . It is not known whether non-ABO antibodies confers any protective effect against SARS-CoV-2 infection or COVID-19 severe illness, alone, or in conjunction with O blood group.

A population-based retrospective cohort study was performed across Ontario, Canada.

Patient-level datasets including all hospitalizations, emergency department visits, and laboratory tests for SARS-CoV-2 were linked using unique encoded identifiers and analyzed at ICES (Ray et al., 2020) .

Patients were included if they had ABO testing and non-ABO antibody screening (group and screen) between January 2007-December 2019, and subsequently, SARS-CoV-2 viral RNA PCR testing between January 15, 2020-November 16, 2020.

Study outcomes included SARS-CoV-2 infection, as well as COVID-19 severe illness or death (Ray et al., 2020) , the latter including venous thromboembolism. Relative risks (RR) were calculated in relation to the presence vs. absence of non-ABO antibodies, including in conjunction with O and non-O blood groups. RR were adjusted for demographic characteristics and comorbidities. An additional analysis was restricted to those who tested positive for SARS-CoV-2 infection.

Statistical analyses were performed using SAS version 9.4 for UNIX (SAS Institute Inc., Cary, NC).

Among 2,659,328 individuals who had an ABO blood group test from January 2007 to December 2019, 413,576 had a subsequent SARS-CoV-2 test and were included in the cohort.

Altogether, 18.6% were aged ≥ 70 years. Patients with a non-ABO antibody (N = 5652 [1.4%])

were older, more likely to be female and affected by more comorbidities than those without an antibody (Table) .

The risk of SARS-CoV-2 infection was not associated with the presence of non-ABO antibodies, including among those who were O blood group (Figure, upper) . While the unadjusted risk was significantly higher in persons with both non-O blood group and non-ABO antibodies (RR 1.86, 95% CI 1.06-2.78), this was not so in the adjusted model (RR 1.28, 95% CI 0.73-1.86), or in the J o u r n a l P r e -p r o o f other groups (Figure, middle) . Restricting to those who tested positive for SARS-CoV-2 virus showed a similar pattern (Figure, lower) .

The risk of SARS-CoV-2 infection or COVID-19 severe illness was not associated with the presence of non-ABO antibodies, even among persons with O blood group.

We did not possess details about which specific non-ABO antibodies were detected in our study sample -only that they were present -yet, since hundreds exist (Gehrie and Tormey, 2014) , any related analysis would be challenging. Non-A, non-B antigens are more prevalent in persons with a hemoglobinopathy, inflammatory disease, and in certain ethnic groups (Wu et al., 2008 ), yet, none of these other factors were accounted for herein.

CoV-2 testing, which was widely available under Ontario's universal health plan. The rate of non-ABO antibodies herein (1.4%) was consistent with that described by others (Gehrie and Tormey, 2014) .

Blood group O may be somewhat protective against SARS-CoV-2 by neutralization of viral particles by the anti-A and anti-B antibodies (Pendu et al., 2021) . In terms of non-ABO antibodies, exposure to an inflammatory RNA molecule heightens the immune response of rodents to a model blood group antigen, leading to alloantigen-specific immunity, as might occur in a viral infection like coronavirus (Gehrie and Tormey, 2014) . Many non-A, non-B antigens serve structural and physiologic functions for red cell homeostasis (Gehrie and Tormey, 2014 ), yet, it is unknown if any can confer protection against a viral infection like SARS-J o u r n a l P r e -p r o o f All authors have seen and approved the final version of the manuscript being submitted. The article is the authors' original work, has not received prior publication, and is not under consideration for publication elsewhere.

Funded by a grant from the Ontario Academic Health Sciences Centre AFP Innovation Fund, and the Ontario Ministry of Health and Long-Term Care.

This study was also supported by ICES, which is funded by an annual grant from the Ontario J o u r n a l P r e -p r o o f Table. Characteristics of 413,577 individuals in Ontario, Canada with known ABO blood group and non-ABO antibody screen status, and who subsequently underwent SARS-CoV-2 viral RNA PCR testing between January 15, 2020 and November 16, 2020. All data are presented as a number (%) unless otherwise indicated. 

The influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: responders, hyper-responders, and non-responders

Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies

ABO blood types and COVID-19: spurious, anecdotal, or truly important relationships? A reasoned review of available data

Blood group antibodies and their significance in transfusion medicine

Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: a population-based cohort study

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

ABO(H) blood groups and vascular disease: a systematic review and meta-analysis